This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis

Update Il y a 4 ans
Reference: EUCTR2009-014368-20

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objectives of this study are to evaluate the efficacy and safety of 2 SC dosing tiers of ustekinumab in the treatment of dolescent subjects 12 to 18 years of age with moderate to severe chronic plaque psoriasis.


Inclusion criteria

  • Moderate to severe plaque-type psoriasis